This a rare condition in which the adrenal gland suffers from abnormal cell growth such as tumor or what is referred to
as a neoplasm.
Not exact matches
«Prudential's methodical actuary,»
as I wrote in Truth, «had gone through his company's own life insurance payouts for the previous year and had discovered that two words kept recurring in the ledgers: malignant
neoplasm.»
These experts decided to rename EFVPTC
as «noninvasive follicular thyroid
neoplasm with papillary - like nuclear features» or NIFTP.
Next on 23andMe's agenda: applying the same approach to rare cancers, such
as sarcoma and a group of blood cancers called myeloproliferative
neoplasms, that are difficult to study but that might be ideally suited to this kind of analysis.
Using a fluorescent protein to detect Rgs16 expression, the investigators found that this gene is induced by pancreatic tumor formation starting from its earliest manifestation
as ductal
neoplasm all the way to advanced solid tumor in a spatially and temporally coincidental manner.
The incidence rate for
neoplasms was highest among children either after IVF (1.5 / 1000) and somewhat lower for OI births (1.0 / 1000)
as compared to that of naturally conceived children -LRB-.59 / 1000).
The lesions evaluated in this study that can become cancerous are known
as intraductal papillary mucinous
neoplasms.
Myeloproliferative
neoplasms (MPN) are diagnosed in around 3,300 UK patients every year and cause an overproduction of blood cells creating a significant impact on quality - of - life, with symptoms such
as night sweats, itching and tiredness.
Each
neoplasm was part of a tissue microarray constructed
as described elsewhere (22).
In 2005, the identification of an activating mutation in JAK2 (the V617F mutation)
as a STAT5 - activating and disease - causing genetic alteration in a significant proportion of patients with myeloproliferative
neoplasms (MPNs) has emphasized the oncogenic role of the JAK tyrosine kinases in hematologic malignancies.2 — 5 JAK2 is a member of the Janus tyrosine kinase family comprising three other mammalian non-receptor tyrosine kinases (JAK1, JAK3 and TYK2) that associate with cytokine receptors lacking intrinsic kinase activity to mediate cytokine - induced signal transduction and activation of STAT transcription factors.6 All JAKs share a similar protein structure and contain a tyrosine kinase domain at the C - terminus flanked by a catalytically inactive pseudokinase domain with kinase - regulatory activity, by an atypical SH2 domain and by a FERM domain that mediates association to the membrane - proximal region of the cytokine receptors.7, 8 Soon after the discovery of JAK2 V617F, we and others described that activating JAK1 mutations are relatively common in adult patients with T - cell acute lymphoblastic leukemia (ALL) and participate in ALL development allowing for constitutive activation of STAT5.9 — 11 Several STAT5 - activating JAK1 mutations were also reported in AML and breast cancer patients.10
FDA Clears Test to Help Diagnose, Identify Blood Cancer Type: The FDA has approved ClearLLab Reagents (T1, T2, B1, B2, M) for the detection of hematologic malignancies such
as acute and chronic leukemias, myelodysplastic syndromes, myeloproliferative
neoplasms, multiple myeloma, and non-Hodgkin lymphoma.
The main diseases that cause an increased excretion of fecal calprotectin are Crohn's disease, ulcerative colitis and
neoplasms such
as bowel cancer.
There is also controversy
as to what criteria should be used to establish whether a lesion that arises in the skin or soft tissues is or is not a
neoplasm, and if so, whether it is benign or malignant.»
A
neoplasm is a tumor that grows
as opposed to one that swells; a benign
neoplasm is non-cancerous, and a malignant
neoplasm is cancer.
These
neoplasms usually appear
as small, red, raised, sparsely haired nodules that often have an ulcerated surface.
Infections, Calculi (forms into cat bladder stones) and
Neoplasms (abnormal cell growth such
as cancer) in the bladder are the main cat bladder problems.
Charges for Treatment (s) of the following Illness (es) or Surgery (ies), which Manifest (ed) themselves or are recommended, or symptoms occur during the first one hundred and eighty (180) days of Coverage hereunder beginning on the initial Effective Date: any condition of the breast; any Treatment of all forms of cancer /
neoplasm; any condition of the prostate; disorders of the reproductive system; hysterectomy; gall stones or urologic stones (kidney, ureteral, bladder or urethral stones) and any associated complications; any acne diagnosis or acne related condition; asthma; allergies; tonsillectomy; back conditions; adenoidectomy; hemorrhoids; hemorrhoidectomy; hernia, or any Surgery (ies) that is (are) not Emergency in nature,
as Emergency is defined hereunder.